Table 1 Patients’ characteristics
Tot | n° (%) Tot 89 (100) |
|---|---|
Sex | |
Male | 61 (68.5) |
Female | 28 (31.5) |
Age | |
Median range | 66.5 |
< 75 | 73 (82) |
> 75 | 16 (18) |
Histotype | |
Adenocarcinoma | 61 (68.5) |
Squamous | 28 (31.5) |
EOCG performance status | |
0 | 43 (48) |
> 1 | 46 (52) |
TPS | |
> 50% | 24 (27) |
< 50% | 31 (35) |
Unknown | 34 (38) |
Therapy for metastatic disease | |
I line therapy | |
Pembrolizumab | 24 (27) |
Pembrolizumab + CHT | 15 (17) |
Ipi/Nivo + CHT | 16 (18) |
II line | |
Nivolumab | 34 (38) |
Smoking status | |
Smoker (current/former) | 11 (12) |
Non-smoker | 78 (88) |
Response to ICIs | |
Yes | 54 (61) |
No | 35 (39) |
Best response rate | |
Partial response | 28 (31.5) |
Stable disease | 18 (20.5) |
Progression | 43 (48) |